Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
AMGN Amgen Inc
- Stocks
- Healthcare
- NASDAQ: AMGN
Price (delayed)
$288.18
Market cap
$154.96B
P/E Ratio
26.08
Dividend/share
$9.26
EPS
$11.05
Enterprise value
$203.53B
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the world's largest independent biotechnology companies, Amgen was established in Thousand Oaks, California, in 1980.
Highlights
The net income has soared by 58% YoY and by 45% from the previous quarter
AMGN's EPS has surged by 57% year-on-year and by 45% since the previous quarter
The P/E is 33% below the last 4 quarters average of 39.2 but 4.3% above the 5-year quarterly average of 25.0
AMGN's gross margin is down by 5% year-on-year but it is up by 2.4% since the previous quarter
AMGN's quick ratio is down by 12% year-on-year and by 9% since the previous quarter
Key stats
What are the main financial stats of AMGN
Market
Valuations
Earnings
Shares outstanding
537.71M
Market cap
$154.96B
Enterprise value
$203.53B
Price to earnings (P/E)
26.08
Price to book (P/B)
24.94
Price to sales (P/S)
4.54
EV/EBIT
20.97
EV/EBITDA
13.32
EV/Sales
5.96
Revenue
$34.13B
Gross profit
$21.5B
Operating income
$7.45B
Net income
$5.93B
EBIT
$9.7B
EBITDA
$15.28B
Free cash flow
$10.92B
Per share
Balance sheet
Liquidity
EPS
$11.05
EPS diluted
$10.96
Free cash flow per share
$20.29
Book value per share
$11.55
Revenue per share
$63.43
TBVPS
$83.64
Total assets
$89.37B
Total liabilities
$83.16B
Debt
$57.38B
Equity
$6.21B
Working capital
$3.92B
Debt to equity
9.24
Current ratio
1.17
Quick ratio
0.74
Net debt/EBITDA
3.18
Margins
Efficiency
Dividend
EBITDA margin
44.8%
Gross margin
63%
Net margin
17.4%
Operating margin
21.8%
Return on assets
6.5%
Return on equity
92.9%
Return on invested capital
13.4%
Return on capital employed
14.6%
Return on sales
28.4%
Dividend yield
3.21%
DPS
$9.26
Payout ratio
83.8%
AMGN stock price
How has the Amgen stock price performed over time
Intraday
1.64%
1 week
6.08%
1 month
-0.94%
1 year
-4.26%
YTD
10.57%
QTD
-7.5%
Financial performance
How have Amgen's revenue and profit performed over time
Revenue
$34.13B
Gross profit
$21.5B
Operating income
$7.45B
Net income
$5.93B
Gross margin
63%
Net margin
17.4%
The net income has soared by 58% YoY and by 45% from the previous quarter
The net margin rose by 43% since the previous quarter and by 37% year-on-year
The revenue has grown by 16% year-on-year and by 2.1% since the previous quarter
The gross profit has increased by 10% year-on-year and by 4.5% since the previous quarter
Price vs fundamentals
How does AMGN's price correlate with its fundamentals
Growth
What is Amgen's growth rate over time
Valuation
What is Amgen stock price valuation
P/E
26.08
P/B
24.94
P/S
4.54
EV/EBIT
20.97
EV/EBITDA
13.32
EV/Sales
5.96
AMGN's EPS has surged by 57% year-on-year and by 45% since the previous quarter
The P/E is 33% below the last 4 quarters average of 39.2 but 4.3% above the 5-year quarterly average of 25.0
Amgen's equity has increased by 24% YoY and by 6% from the previous quarter
The stock's price to book (P/B) is 16% less than its 5-year quarterly average of 29.8 and 2.2% less than its last 4 quarters average of 25.5
The revenue has grown by 16% year-on-year and by 2.1% since the previous quarter
The P/S is 11% less than the 5-year quarterly average of 5.1 and 9% less than the last 4 quarters average of 5.0
Efficiency
How efficient is Amgen business performance
AMGN's return on assets has surged by 59% year-on-year and by 44% since the previous quarter
The ROE has soared by 59% YoY and by 38% from the previous quarter
The ROIC has grown by 34% YoY and by 28% from the previous quarter
AMGN's return on sales is up by 22% since the previous quarter and by 12% year-on-year
Dividends
What is AMGN's dividend history
DPS
$9.26
Dividend yield
3.21%
Payout ratio
83.8%
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did Amgen financials performed over time
Amgen's total assets is 7% more than its total liabilities
Amgen's current ratio has decreased by 18% YoY and by 7% from the previous quarter
AMGN's quick ratio is down by 12% year-on-year and by 9% since the previous quarter
AMGN's debt to equity is down by 28% YoY and by 10% QoQ
Amgen's equity has increased by 24% YoY and by 6% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.